Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Dicato

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
The Oncologist|July 1, 2008
Venous thromboembolic events and erythropoiesis-stimulating agents: an updateMario Dicato
Seminars in Oncology|June 26, 2002
High-dose chemotherapy in breast cancer: where are we now?Mario Dicato
The Oncologist|March 11, 2003
Anemia in cancer: some pathophysiological aspectsMario Dicato
The Oncologist|September 19, 2009
Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic eventsJoachim Fandrey, Mario Dicato
Current Opinion in Oncology|May 26, 2010
Erythropoietin in cancer patients: pros and consMario Dicato, Laurent Plawny
Seminars in Cancer Biology|February 20, 2020
Immune-modulating and anti-inflammatory marine compounds against cancerCristina Florean, Mario Dicato, Marc Diederich
Genes & Nutrition|November 19, 2015
Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancerFrançois Gaascht, Mario Dicato, Marc Diederich
Biochemical Pharmacology|July 19, 2014
Modulatory roles of glycolytic enzymes in cell deathClaudia Cerella, Mario Dicato, Marc Diederich
Cancer Letters|June 26, 2014
Epigenetic modulators from "The Big Blue": a treasure to fight against cancerMichael Schnekenburger, Mario Dicato, Marc Diederich
Current Pharmaceutical Biotechnology|May 6, 2015
Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cellsCindy Grandjenette, Mario Dicato, Marc Diederich
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
The Oncologist|July 1, 2008
Venous thromboembolic events and erythropoiesis-stimulating agents: an updateMario Dicato
Seminars in Oncology|June 26, 2002
High-dose chemotherapy in breast cancer: where are we now?Mario Dicato
The Oncologist|March 11, 2003
Anemia in cancer: some pathophysiological aspectsMario Dicato
The Oncologist|September 19, 2009
Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic eventsJoachim Fandrey, Mario Dicato
Current Opinion in Oncology|May 26, 2010
Erythropoietin in cancer patients: pros and consMario Dicato, Laurent Plawny
Seminars in Cancer Biology|February 20, 2020
Immune-modulating and anti-inflammatory marine compounds against cancerCristina Florean, Mario Dicato, Marc Diederich
Genes & Nutrition|November 19, 2015
Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancerFrançois Gaascht, Mario Dicato, Marc Diederich
Biochemical Pharmacology|July 19, 2014
Modulatory roles of glycolytic enzymes in cell deathClaudia Cerella, Mario Dicato, Marc Diederich
Cancer Letters|June 26, 2014
Epigenetic modulators from "The Big Blue": a treasure to fight against cancerMichael Schnekenburger, Mario Dicato, Marc Diederich
Current Pharmaceutical Biotechnology|May 6, 2015
Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cellsCindy Grandjenette, Mario Dicato, Marc Diederich
Pageof 16